Phase I clinical trial of IMM2902 completed the first patient enrollment and dosing in the United States.

On June 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that, on June 20, local time, an FDA-registered Phase I clinical trial of the first globally novel bi-specific antibody-rec......

2022-06-21

IMM2902 Invention Patent was Authorized by the US Patent Office

On June 16, 2022, Immuneonco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the first bispecific antibody-receptor recombinant protein targeting human CD47 x HER2 (IMM2902), authorized by the United States Pate......

2022-06-16

ImmuneOnco’s IMM27M，an ADCC-enhanced CTLA-4 antibody completed the first patient enrollment and dosing

On June 15, 2022, Immuneonco Biopharmaceuticals(Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that our newly developed ADCC-enhanced CTLA-4 antibody (IMM27M) completed the first patient enrollment and first dosing. The administration ......

2022-06-15

The Phase Ib/II clinical study of IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors completed the first patient enrollment and administration

On May 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the FPI in the Phase Ib/II clinical study of first domestic SIRPα-Fc fusion protein targeting human CD47 (project number: IMM01) combin......

2022-05-17

ImmuneOnco was invited to give an oral presentation at the PEGS Boston Summit

In May 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") was invited to participate in the PEGS Boston Summit held in Boston, USA. Dr. Tian Wenzhi, founder, chairman and CEO of ImmuneOnco, authorized Dr. Zh......

2022-05-10